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Abstract
Human beta-defensin 2 (DEFB4, also known as DEFB2 or hBD-2) is a salt-sensitive antimicrobial
protein that is expressed in lung epithelia. Previous work has shown that it is encoded in a cluster
of beta-defensin genes at 8p23.1, which varies in copy number between 2 and 12 in different
individuals. We determined the copy number of this locus in 355 patients with cystic fibrosis (CF),
and tested for correlation between beta-defensin cluster genomic copy number and lung disease
associated with CF. No significant association was found.
Background
Cystic fibrosis (CF) is an autosomal recessive genetic dis-
ease in epithelia (Online Mendelian Inheritance in Man
(OMIM) 219700, http://www.ncbi.nlm.nih.gov), with
chronic lung infection being the major cause of morbidity
and mortality. It has a a carrier frequency of about 1 in 25
in the United Kingdom, and the disease is due to muta-
tions in the cystic fibrosis transmembrane conductance
regulator gene (CFTR) gene, which encodes a membrane
chloride channel (OMIM 602421). There is a wide spec-
trum of different mutations known to cause CF, but the
most common is the ∆F508 mutation, which exists in the
European population as a polymorphic allele with a fre-
quency of between 2 and 3%.
The course of lung infection can vary greatly between
patients with the same CFTR mutation, and despite the
wide spectrum of disease causing mutations, only a few
correlate with lung disease severity. The search for genetic
loci modifying lung disease in CF patients has produced
several candidates, with the gene for mannose binding
lectin (MBL) being the most notable. MBL is a part of the
innate immune system, and low MBL in serum has been
associated with infections in both adults and children
[1,2]. Several studies have reported links with severity of
CF lung disease, although the conclusion regarding the
impact of the heterozygous deficient state differ amongst
these [3-5].
Like MBL, beta-defensins are an important part of innate
immunity. The peptide human beta-defensin 2 (encoded
by the gene DEFB4, also known as DEFB2 or hBD-2) has
been identified as a salt-sensitive antibacterial agent
expressed in the lung airway [6]. Given the chronic bacte-
rial colonisation of the lungs, this is a potential candidate
for a CF modifier locus. It is possible that variation in
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DEFB4 levels could cause changes in the antibacterial
effectiveness of airway surface fluid. Deterioration in lung
function during clinical progress of CF is correlated with
DEFB4 expression levels, suggesting again that DEFB4 has
an important antibacterial role in airway surface fluid [7].
Additionally,  DEFB4  expression is up-regulated by
mucoid  Pseudomonas aeruginosa, and has very effective
bactericidal activity against it [8,9], but another important
pathogen in CF lungs, Burkholderia cepacia, is not killed by
airway surface fluid expressing DEFB4 [10].
Three beta-defensins are expressed in significant levels in
airway epithelia: human beta-defensin 1 (DEFB1) which
is expressed in the lung [11], human beta-defensin 3
(DEFB103, also known as DEFB3 or hBD-3) which is
expressed in the trachea [12], and DEFB4, also expressed
in the lung [6]. All three genes are part of a beta-defensin
cluster at chromosomal locus 8p23.1 [13]. This cluster of
beta defensins, with the exception of DEFB1, has been
shown to be on a repeat unit of at least 260 kb which var-
ies in copy number in different people. Individuals can
have between 2 and 12 copies, with most individuals hav-
ing 3, 4 or 5 copies, and copy number is correlated with
basal unstimulated expression level of DEFB4  in lym-
phoblastoid cell lines [14]. There have been several
genome-wide studies confirming this copy number varia-
tion [15-17], and they highlight this type of large scale
genomic polymorphism as an underappreciated source of
phenotypic variation. Indeed, there is evidence that varia-
ble CCL3L1 gene copy number is associated with suscep-
tibility to HIV infection [18].
The hypothesis that we wished to test in this study was
that copy number variation of this beta-defensin cluster
(and, by implication, DEFB4) is associated with lung dis-
ease in CF patients.
Results
We determined beta-defensin cluster copy number for
355 CF patients, of whom 343 had full clinical data. 159
patients were ∆F508 CFTR homozygotes, 141 were ∆F508
CFTR heterozygotes and 43 had non-∆F508 mutations on
both chromosomes. The mean age was 29.1 ± 8.9 years
and 57% were male. Figure 1 shows the distribution of
beta-defensin copy number phenotypes in the full CF
patient cohort. There was no difference in the copy
number phenotype distribution between this cohort and
a random sample of 167 normal UK individuals (E.J.Hol-
lox and J.A.L.Armour unpublished data).
Each analysis was performed with the whole cohort, and
with the ∆F508 CFTR homozygotes only. There were no
significant correlations between beta-defensin copy
number and each respiratory clinical parameter measured
(mean and current FEV1, mean and current FVC). The
patients were then arbitrarily divided into two groups
based on copy number: one group comprising patients
with 3 and fewer copies of the β-defensin region (n = 77),
and another group with patients who have 4 copies and
more (n = 266). Differences in lung function and inflam-
matory marker status were tested using two-tailed Mann-
Whitney U-tests, differences in infection status were tested
using χ2 tests. With this sample size, a difference of 9% in
FEV1 median between the two groups could be detected
with 80% power. No significant differences between any
two groups were seen.
We also decided to determine the effectiveness of micros-
atellite dosage ratios in reinforcing, or possibly acting as a
replacement for, MAPH in determining copy number. We
analysed a subset of samples with copy numbers of three
or four by determining the genotype of a microsatellite in
the intron of DEFB4. The allelic distributions are shown in
Figure 2. Out of 114 samples tested, 81 gave informative
results, of which 71 (88%) agreed with the determination
by MAPH. The samples that differed typically gave
unrounded MAPH scores between the two values (range
3.42–3.54 or 4.5–4.54), and may be due either to error
rate or, perhaps more likely given the small confidence
intervals of each MAPH result (see Methods) and its relia-
bility for other loci [19-23], genuine copy number hetero-
geneity between probes across the repeats. We should be
able to distinguish between genuine copy number hetero-
geneity and MAPH error rate by analysing the copy
number estimate given by the DEFB4 probe alone, which
is 735 bp from the microsatellite in the intron of DEFB4,
and should report the same copy number as the microsat-
Beta-defensin diploid copy number distribution in the cohort  of 355 cystic fibrosis patients analysed Figure 1
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ellite. Analysis of this copy number estimate for the 10
discrepant results shows that it agrees with the microsatel-
lite estimate for 5 samples. Therefore, the error rate in dis-
tinguishing 3 from 4 copies by MAPH is 5/81 = 6%. The
result also suggests that copy number heterogeneity
involving the DEFB4 probe (probe F) has a frequency of
around 6%. In addition, copy number heterogeneity
involving MAPH probe H has been found in several well-
characterised individual DNAs (E.J.Hollox, J.A.L.Armour
and J.C.K.Barber, unpublished data).
Discussion
This is the first study to test the hypothesis, raised in a pre-
vious paper [14], that variable β-defensin genomic copy
number affects immune system function; in this case lung
infection in a susceptible CF patient cohort. From the data
we have presented, it is clear that either β-defensin
genomic copy number has no effect on lung function in
CF patients, or that any effect is too small for it to be
detected using this cohort size. We cannot formally rule
out an effect of single nucleotide polymorphisms (SNPs)
within or surrounding the DEFB4 gene, given the appar-
ent lack of association between copy number alleles and
microsatellite alleles, and by inference any single nucle-
otide polymorphism (SNP). Any further study on these
SNPs will have to carefully consider the copy number var-
iation at this locus, given that a single nucleotide change
could not only be allelic but differ between paralogues on
the same chromosome [16].
There could be two reasons why β-defensin genomic copy
number has no effect on lung function in CF patients.
Firstly, unlike in cultured lymphocytes [14], there may be
no correlation between DEFB4 copy number and gene
expression in lung epithelia. Ideally a positive correlation
between DEFB4 copy number and DEFB4 expression lev-
els in non-inflamed lungs should be established, but real-
istically such studies are difficult to perform for both
technical and ethical reasons. Even if such a direct link
were proved, the lung in CF patients is characterised by a
strong inflammatory response, and, given the dramatic
increase in DEFB4 peptide levels in inflamed tissue [24],
this could hide any differences in basal expression levels
due to genomic copy number variation. Secondly, differ-
ences in DEFB4 expression are masked by other factors in
the CF lung: for example, elastolytic cathepsins which
breakdown DEFB4 and DEFB103 are present in the CF
lung, but not in the healthy lung [25]. A recent report
studying single nucleotide variation in the DEFB1 gene
and lung function in CF patients has found no link, pro-
viding further evidence against beta-defensins modifying
lung function in CF patients [26].
The key to further progress is to understand role of antimi-
crobial peptides in the inflamed lung, and exactly how
they contribute to airway surface defence. A recent paper
shows that DEFB4 is more than an antimicrobial peptide,
and attracts neutrophils to sites of inflammation and
infection [27], so it is possible that its chemoattractant
role is as important in the lung as its antimicrobial role.
How DEFB4 interacts with other components of the
inflammatory response, and the innate and adaptive
immune response, is only just beginning to be under-
stood, and it is clear that much more work is needed
before we understand these processes in lung disease.
Methods
Patient samples
DNA was extracted from peripheral blood from cystic
fibrosis patients using the QIAamp DNA Blood Midi kit
(Qiagen) according to the manufacturer's recommenda-
tions as part of a larger modifier gene study. Samples were
coded and anonymised. All participants gave informed
consent and the study was approved by the Royal Bromp-
ton Hospital and Harefield NHS Trust Ethics Committee.
Clinical parameters
Clinical data were obtained from the clinical databases,
patients' hospital notes and computerised microbiology
reports. Forced expiratory volume in 1 second (FEV1) and
forced vital capacity (FVC) were obtained from annual
lung function laboratory records, had been corrected for
sex, age and height and are expressed as percent of pre-
dicted normal values. Annual values were recorded where
available from 1990–2002 and annual rate of decline was
calculated for all subjects with 2 or more values after lin-
ear regression of all available data. Transcutaneous oxygen
saturation with the patient breathing room air was
obtained at the annual visit, and a record of the require-
ment for supplementary oxygen was made. Additional
data included the presence of infection with P. aeruginosa
Allelic distribution of DEFB4 microsatellite (EPEV-2) alleles in  individuals with three and four copies of the beta-defensin  gene cluster Figure 2
Allelic distribution of DEFB4 microsatellite (EPEV-2) alleles in 
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or B. cepacia and most recent total white blood cell count,
C-reactive protein and liver function tests.
Multiplex amplifiable probe hybridisation (MAPH)
MAPH was carried out essentially as previously described
[28,29], with fluorescent detection of amplification prod-
ucts by an Applied Biosystems 3100 Genetic Analyzer. A
probe set including six probes mapping to the beta-
defensin cluster was constructed (Table 1). The values for
these six probes were normalised first for lane intensity
against control subtelomeric probes in the same probe set
which do not show copy number variation [20]. These
ratios were then calibrated against a weighted average of
two control genomic samples in the same experiment,
usually N8 (3 copies) and N25 (7 copies) to get a value for
the number of copies of each probe per diploid cell [14].
In two instances, two other known controls were used on
duplicate samples (European Collection of Animal Cell
Cultures (ECACC) samples BO0183 3 copies – AF0105 4
copies). Of the 355 samples tested, 205 were tested in
duplicate. Copy number was calculated by averaging the
values of each probe mapping to this region and present-
ing the data both as a mean value +/- 95% confidence
intervals (CIs), and as a rounded integer, representing the
most likely copy number. Initially all six probes were used
in the calculation, but it was found that DEFB104 probe
was unusually sensitive to DNA quantity and removing
the values for that probe in many cases improved the con-
fidence intervals. All data in this paper are from five
probes only. The 95% CIs for each copy number reading
in the full cohort ranged from 0.05 to 1.2 with a median
value of 0.24.
Microsatellite analysis
A microsatellite (EPEV-2) in the intron of DEFB4, was
amplified using the following primers (EPEV-2F 5'-
GCACCAGAGACCTCATGTTTTC-3' and EPEV-2R 5'-
GTAACTTACAGTTGAAAACCAC-3'), with EPEV-2F 5' flu-
orescently-labelled with 6-FAM. The PCR conditions were
as follows: 0.2 mM each of dATP, dCTP, dGTP, dTTP, 1
mM MgCl2, 75 mM Tris-HCl (pH 8.8 at 25°C), 20 mM
(NH4)2SO4, 0.01% (v/v) Tween 20 in a final volume of 10
µl, with 5 pmol of each primer, 10 ng genomic DNA, 0.5
units Taq DNA polymerase (ABgene), followed by cycling
for 25 cycles at 95°C 1 minute, 60°C 1 minute 72°C 1
minute, and a final extension incubation of 72°C 20 min-
utes. 1.5 µl of the PCR product was mixed with 10 µl Hi-
Di formamide and run on an ABI 3100 using standard
conditions, with G500 ROX marker. Allelic sizes ranged
from 240 bp to 272 bp, and samples were omitted from
analysis if stutter peaks made the interpretation of allele
peak areas or allele lengths ambiguous.
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